Published on

November 25, 2025

Last updated on

January 27, 2026

China NMPA Issues Extensive Policy Plan to Reform Cosmetics Regulation

China’s National Medical Products Administration (NMPA) issued a major policy blueprint on November 17, 2025 with the release of its “Opinions on Deepening the Reform of Cosmetics Supervision and Promoting High-Quality Development” (referred to as the “Opinions”). The Opinions set China’s long-term direction for upgrading cosmetics regulation, strengthening technical capacity, and expanding the use of non-animal testing methods.

The roadmap provides foreign companies with early insight into planned regulatory changes that will shape future filings and compliance obligations, although many measures will still require detailed implementing rules.

At a Glance: What Global Cosmetics Companies Need to Know

The NMPA highlights several priority areas that will guide upcoming regulatory updates. Key developments foreign companies should monitor include:

Stakeholder impacts: Faster routes for innovative and cruelty-free products, clearer regulatory expectations, and stronger demand for new cosmetic ingredients.
Innovation and testing: Expanded acceptance of in-vitro data, broader use of alternative methods, and updated guidance for new ingredient development.
Support mechanisms: Access to pre-submission consultation and streamlined requirements for eligible first-launch products in China.
Registration efficiency: Simplified filing pathways, shorter technical review timelines, clearer documentation expectations, and improved national–provincial coordination.
Market access and oversight: Expanded electronic labeling, updated retail and e-commerce obligations, and strengthened post-market safety monitoring.

Continue reading for a deeper analysis of the reforms and how they may affect your China market strategy — or contact Cisema’s regulatory experts for tailored guidance.

Regulatory Context: China’s 2030–2035 Cosmetics Roadmap

The NMPA’s roadmap sets out how China plans to modernize its cosmetics supervision system over the coming decade. By 2030, China aims to establish a more complete legal, technical, and standards framework for the sector. By 2035, the supervision system is expected to reach an internationally advanced level and support stronger global competitiveness.

Key Regulatory Updates and Stakeholder Implications

Building on this long-term direction, the Opinions introduce major policy measures to streamline NMPA cosmetics registration, strengthen safety oversight, and advance innovation — including a broader shift toward alternative non-animal testing methods.

These developments will affect stakeholders across the value chain:

Cosmetics brands: Clearer pathways for innovative products, expanded electronic labeling options, and more efficient administrative procedures.
Ingredient suppliers: More structured management of new ingredients and possible access to local incentives for high-quality raw material innovation.
Regulatory and technical teams: Clearer requirements, updated technical pathways, and more consistent review expectations.

Accelerated Innovation and a Shift Away From Animal Testing

China is updating its scientific evaluation system to expand non-animal testing pathways for cosmetic products and support faster development of new ingredients and formulations, including cruelty-free products.

Key policy directions include:

Updates to ingredient management and classification rules to better support innovative products
Strengthened technical guidance for new ingredient submissions, including expanded evaluation pathways and pre-submission consultation channels
Broader application of NMPA-recognized alternative in-vitro methods to reduce animal testing
Priority development of non-animal alternative testing methods for hair-perming products, non-oxidizing hair dyes, and monitored new raw materials
Potential exemptions from overseas-sales proof for eligible international products first launched in China

These changes may shorten approval timelines for cosmetic products containing novel ingredients (such as botanicals like bakuchiol) when supported by accepted in-vitro data.

Faster Registration and Smoother Technical Reviews

The Opinions commit to introducing structural improvements to make cosmetic filing and registration workflows more consistent and reduce administrative friction.

Key policy directions include:

Simplified cosmetic and ingredient registration and filing processes, supported by clearer documentation requirements
Permission to use shared safety data for formula variations
Shortened technical review timelines
Improved coordination between national and provincial review bodies

Updated Market Access and Retail Compliance Requirements

Reflecting changes in consumer behavior and supply chain models, the reform also introduces updates affecting commercial operations and retail compliance across online and offline sales channels of cosmetic products.

Key policy directions include:

Support for senior-focused product R&D aligned with supporting China’s “silver economy”
Broader use of electronic labeling to enhance traceability
Strengthened compliance duties for e-commerce platforms

These initiatives reflect China’s increasing focus on lifecycle supervision and digitalized regulatory management.

Stronger Post-Market Controls and Risk Management

China is enhancing cosmetic lifecycle-based supervision to identify risks earlier and maintain higher product safety standards.

Key policy directions include:

Enhanced adverse reaction monitoring and reporting mechanisms
Integrated risk-based supervision and lifecycle safety responsibilities across enterprises and product categories
Continued development of quality oversight mechanisms

Once technical rules are released, these enhancements will raise expectations for internal monitoring and quality systems across all market participants.

Deeper International Integration and Standards Alignment

China plans to strengthen cooperation with global regulators through continued participation in ICCR and similar initiatives. The Opinions also call for faster adoption of internationally recognized safety, efficacy, and quality requirements, improving predictability for multinational manufacturers and supporting smoother cross-market operations.

Next Steps for Foreign Manufacturers and Ingredient Suppliers

As China transitions to a more science-driven and digitally enabled regulatory system, overseas companies can take several focused actions to stay ahead of upcoming requirements and maintain a strong compliance position.

Review Policy Changes and Conduct Gap Analysis

Begin with a close review of the “Opinions” to understand how the reforms affect your current processes. Mapping the updated requirements against existing documentation and oversight systems helps identify where adjustments are needed.

A structured gap analysis helps clarify:

Needed adjustments to meet clearer dossier standards
Revisions to integrate accepted in-vitro and alternative methods
Enhancements to monitoring systems for adverse reaction reporting

Cisema can support this review, providing access to the full policy text and detailed regulatory interpretation.

Optimize Product and Ingredient Strategy

The reform also provides an opportunity to reshape cosmetic product and ingredient planning with a more forward-looking approach.

Companies may consider:

Prioritize R&D areas supported by policy direction, such as silver-economy products, compliant plant-based formulations, and other innovative materials
Adjust launch timelines to benefit from streamlined reviews
Reassessing ingredient portfolios (especially new or monitored materials) to align with evolving classification rules and the new-ingredient management system

Proactive planning helps ensure that future launches remain feasible and aligned with China’s regulatory developments.

Strengthen Quality and Safety Management Systems

As the reform places greater emphasis on lifecycle-based supervision, companies should reinforce internal controls to align with the enhanced post-market requirements.

Practical enhancements include:

Upgrading quality management systems to support expanded risk-based oversight and electronic labeling traceability
Enhancing safety assessment capabilities to generate reliable in-vitro data
Implementing stronger risk-monitoring and early-warning tools for adverse reaction reporting

These improvements will support more consistent submission outcomes and stronger post-market performance as regulatory expectations continue to evolve.

Final Thoughts: Turn Regulatory Change Into Strategic Advantage

China’s cosmetics supervision reform marks a decisive step toward a more science-driven, innovation-oriented, and internationally aligned regulatory system. With detailed implementation guidelines still forthcoming, overseas companies should stay alert to upcoming technical documents that will clarify timelines, transition arrangements, and procedural expectations.

In this shifting environment, early adjustment of internal systems will be key to keeping product pipelines on track. For over 20 years, Cisema has supported companies through regulatory transitions — from policy interpretation and internal training to regulatory strategy and full agency support for cosmetics registration and compliance.

For expert guidance on NMPA cosmetics registration or compliance planning under the new reforms, connect with Cisema’s regulatory specialists today.

Further Information

Explore Cisema’s China NMPA Cosmetics registration services

References

The following official resources from the National Medical Products Administration provide the complete policy text, accompanying news release, and detailed regulatory interpretation for the new cosmetics reform measures: